In part 2 of this series, board-certified nurse practitioner Lucia Novak, director of Riverside Diabetes Center, discusses the benefits of long-acting insulins and barriers that may prevent more widespread implementation of these therapies. For more, visit www.consultant360.com.

In part 2 of this series, board-certified nurse practitioner Lucia Novak, director of Riverside Diabetes Center, discusses the benefits of long-acting insulins and barriers that may prevent more widespread implementation of these therapies. For more, visit www.consultant360.com.

Dr Maria Suarez-Almazor discusses the prevalence of patient nonadherence to medications in a rheumatology setting, how a provider can improve their patient/provider relationship, and more.

Dr Maria Suarez-Almazor discusses the prevalence of patient nonadherence to medications in a rheumatology setting, how a provider can improve their patient/provider relationship, and more.

Dr Maria Suarez-Almazor discusses the prevalence of patient nonadherence to medications in a rheumatology setting, how a provider can improve their patient/provider relationship, and more.

Dr Stephen Kopecky from Mayo Clinic talks about nonpharmacologic and pharmacologic options for preventing atrial fibrillation.

Dr Stephen Kopecky from Mayo Clinic talks about nonpharmacologic and pharmacologic options for preventing atrial fibrillation.

Dr Stephen Kopecky from Mayo Clinic talks about nonpharmacologic and pharmacologic options for preventing atrial fibrillation.

Many patients already struggle to afford their necessary prescriptions, but the prices of hundreds of drugs — including some generics — are set to rise even higher this year. In a podcast interview with Consultant360, Dr David Nash, founding dean of the Jefferson College of Population Health and chair of the 19th Population Health Colloquium, discusses the patient- and provider-level impact of rising pharmaceutical prices, and outlines steps he says are needed to truly address the issue. For more, visit www.consultant360.com.

Many patients already struggle to afford their necessary prescriptions, but the prices of hundreds of drugs — including some generics — are set to rise even higher this year. In a podcast interview with Consultant360, Dr David Nash, founding dean of the Jefferson College of Population Health and chair of the 19th Population Health Colloquium, discusses the patient- and provider-level impact of rising pharmaceutical prices, and outlines steps he says are needed to truly address the issue. For more, visit www.consultant360.com.